Efficacy and safety signals from early-phase studies of KRAS inhibition in pancreatic cancer
GastroenterologiaSobre o estudo
- Desenho
- Metanálise
- Nível de evidência
- 1 · Evidência consolidada
- Revista
- Scientific reports
- Publicado em
- 11 mar 2026
- Citações
- 4
O resumo deste estudo é do publisher e não tem licença aberta: por isso mostramos aqui só os dados do estudo, e o texto fica na fonte original, nos links abaixo.
O estudo original
Efficacy and safety signals from early-phase studies of KRAS inhibition in pancreatic cancer
Kathlen Oliveira Martins Tiede, Maria Fernanda Teixeira, Mariana Moura, Ohana Chiaini, Fernando Moura, Mohamad Bassam Sonbol, Mitesh Borad, Tanios Bekaii-Saab, Pedro Luiz Serrano Uson Junior
Descritores MeSH
- Antineoplastic Agents
- Pancreatic Neoplasms
- Proto-Oncogene Proteins p21(ras)
- Carcinoma, Pancreatic Ductal
- Molecular Targeted Therapy
- Humans
- Mutation
- Treatment Outcome
Veja também
Estudos relacionados
- Prognostic value of KRAS gene mutations in pancreatic ductal adenocarcinoma: a systematic review and meta-analysis
- How to find a needle in a haystack: a systematic review on targeting KRAS wild-type pancreatic cancer
- Prognostic utility of preoperative and postoperative KRAS-mutated circulating tumor DNA (ctDNA) in resected pancreatic ductal adenocarcinoma: A systematic review and meta-analysis
- Therapeutic targeting of STAT3 pathways in pancreatic adenocarcinoma: A systematic review of clinical and preclinical literature